Saracatinib (AZD0530)

目录号:S1006

Saracatinib (AZD0530) Chemical Structure

Molecular Weight(MW): 542.03

Saracatinib (AZD0530)是一种有效的Src抑制剂,无细胞试验中IC50为2.7 nM,对c-Yes, Fyn, Lyn, Blk, Fgr和Lck也具有活性;但对Abl和EGFR (L858R和L861Q)活性较低。Phase 2/3。

规格 价格 库存 购买数量  
RMB 746.35 现货
RMB 569.55 现货
RMB 1395.95 现货
RMB 5472.84 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献39篇:

客户使用该产品的9个实验数据:

  • Saracatinib (AZD0530) administration alleviates provocative tumor formation conferred by LHBs exp ression. A and B, cell proliferation assay for Huh7 cells (A) and SK-Hep1 cells (B) after stable LHBs expression under treatment with saracatinib(1 μmol/L). *, P < 0.05.

    Cancer Res 2012 71, 7547-57. Saracatinib (AZD0530) purchased from Selleck.

    C and D, in vivo subcutaneous tumor growth curves (C) and tumor weight quantification of intersected subcutaneous tumor tissues (D) of Huh7 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n =18). *, P < 0.05. E and F,in vivo subcutaneous tumor growth curves (E) and tumor weight quantification of intersected subcutaneous tumor tissues (F) of SK-Hep1 cells after stable LHBs expression under saracatinib treatment (25 mg/kg body weight daily for 4 weeks; n = 18). *, P < 0.05.

    Cancer Res 2013 71, 7547-57. Saracatinib (AZD0530) purchased from Selleck.

  • Dose response studies. HT29-BSRwt cells cultured on 48-well plates were treated with increasing concentrations of saracatinib for 2h. The changes in normalized bioluminescence activity (Fluc/Gluc) were plotted as fold induction over vehicle-treated values. Western blotting analysis with phospho-tyrosine, phospho-Src, and total Src-specific antibodies was performed to confirm the inhibition of Src activity.

    Theranostics, 2016, 6(4):594-609. Saracatinib (AZD0530) purchased from Selleck.

    cells treated for 1 hour with Src inhibitor AZD0530 (50 mmol/L), or the same volume of dimethyl sulfoxide, before TRAIL treatment (at concentrations described earlier) for 24 hours prior to alamar blue assay.

    Mol Cancer Res 2011 9, 249-258. Saracatinib (AZD0530) purchased from Selleck.

  • MCF7 cells were plated in triplicate and treated with vehicle (VEH, DMSO) , AZD0530 (125 nM), AZD7762 (50 nM) or AZD7762 and AZD0530. Cells were isolated 48 h after exposure and subjected to the indicated various cell viability assays. Data for each assay is the mean of all data points from two studies(* p < 0.05 greater than CHK1 inhibitor value).

    Cancer Biol Ther 2011 12(3), 215-28. Saracatinib (AZD0530) purchased from Selleck.

     

    The TMZ-induced caveolin-1 modulation is Src-dependent in Hs683 GBM cells Western blot analyses of soluble caveolin-1 expression in Hs683 glioma cells treated with TMZ (100 μM) four times per week (day 1-4) for 7 h/d, the EGFR inhibitor (10 μM) (erlotinib; day 1), the Src inhibitor AZD0530 (10 μM) (day 1), and combination of the inhibitors and TMZ (+TMZ) compared with control untreated cells (Ct). Soluble caveolin-1 expression was measured on day 5.

    Transl Oncol 2011 4, 92-100. Saracatinib (AZD0530) purchased from Selleck.

  • J Biomol Screen 2013 18, 54-66. Saracatinib (AZD0530) purchased from Selleck.

    Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5. 

    J Biomol Screen 2013 18, 54-66. Saracatinib (AZD0530) purchased from Selleck.

  • IP assay of tyrosine phosphorylation of VDR in the plasmamembrane. Primary human hepatocytes were treated with Veh, 1α, 25(OH)2-VD3 (50nM), LCA-acetate (10 μM), and/or the c-Src inhibitor AZD0530 (AZD) (5 μM) for 6 h.A rabbit anti-VDR antibody was used to immunoprecipitate VDR from cell membrane extracts (300 μg). A mouse anti-phospho-tyrosine was used to detect phosphotyrosines in VDR. A mouse anti-VDR was used to detect immunoprecipitated VDR. Ten % cell extract was set aside as input. Q-PCR assay of the effects of AZD on CYP7A1,CYP27A1, and CYP24A1 mRNA expression in primary human hepatocytes. Primary human hepatocytes were treated with Veh, 1α, 25(OH)2-VD3 (50 nM), LCA-acetate (10 μM), and/or AZD (5 μM) for 16 h. An $, *, or # indicates statistically significant difference, p < 0.05, AZD-treated versus vehicle control, 1α, 25(OH)2-VD3 or LCAacetate-treated versus vehicle control, or 1α, 25(OH)2-VD3 plus AZD or LCA-acetateplus AZD co-treated versus 1α, 25(OH)2-VD3 or LCA-acetate-treated. All the datarepresent one of three separate experiments using primary human hepatocytes from different liver donors (#HH1479, #HH1483, #HH1493, #HH1524, #HH1560, and#HH1567).

     

     

    2010 Dr. Shuxin Han of Kent State University. Saracatinib (AZD0530) purchased from Selleck.

产品安全说明书

Src抑制剂选择性比较

生物活性

产品描述 Saracatinib (AZD0530)是一种有效的Src抑制剂,无细胞试验中IC50为2.7 nM,对c-Yes, Fyn, Lyn, Blk, Fgr和Lck也具有活性;但对Abl和EGFR (L858R和L861Q)活性较低。Phase 2/3。
特性 Saracatinib是第一个作用于人类肿瘤组织Src通路的抑制剂。
靶点
c-Src [2]
(Cell-free assay)
LCK [2]
(Cell-free assay)
c-YES [2]
(Cell-free assay)
EGFR (L861Q) [2]
(Cell-free assay)
Lyn [2]
(Cell-free assay)
2.7 nM <4 nM 4 nM 4 nM 5 nM
体外研究

Saracatinib也有效抑制其他Src酪氨酸激酶家族成员,包括c-Yes, Fyn, Lyn, Blk, Fgr, 和Lck,IC50为4到10 nM。Saracatinib有效抑制SrcY530F突变的NIH 3T3细胞,IC50为80 nM。在NBT-II膀胱癌细胞中,Saracatinib显著阻断HT1080细胞通过立体骨胶原基质的入侵,且完全抑制EGF诱导的细胞分散。[1]Saracatinib作用于DU145和PC3细胞,通过抑制Y419磷酸化而有效抑制Src激活。Saracatinib抑制前列腺癌包括PC3, DU145, CWR22Rv1和 LNCaP的生长,而Saracatinib作用于 LAPC-4, PZ-HPV7和RWPE-1细胞时却显示低活性。Saracatinib使细胞周期停止在G1/S期,但是不使caspase 3断裂。Saracatinib 也明显抑制Boyden 小室的DU145和PC3 移动。[2]Saracatinib有效且持久抑制Akt,且增强A549和Calu-6细胞对放射处理的敏感性。[3]Saracatinib在活性,再吸收,及组成上抑制蚀骨细胞。Saracatinib也可逆阻断蚀骨细胞前体的移动。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
CTV-1 M{DVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jCeWlEPTB;MD6wOlE1OyEQvF2= M{PLcHNCVkeHUh?=
LAMA-84 M1;4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEK1U|BKSzVyPUCuNVU6QSEQvF2= M3L1U3NCVkeHUh?=
MEG-01 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X0cmlEPTB;MD6yN|Y5QCEQvF2= Ml;mV2FPT0WU
EM-2 M3rm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTBwMk[1JO69VQ>? M17qbHNCVkeHUh?=
TE-15 M{XDbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPJTWM2OD1yLkK3OFEzKM7:TR?= MYfTRW5ITVJ?
NCI-H1648 NYPLWHJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r3bmlEPTB;MD6yPFEyPiEQvF2= M1jqVnNCVkeHUh?=
TE-12 M1HYXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXu0S29bUUN3ME2wMlMzPjhizszN MWjTRW5ITVJ?
LB996-RCC MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;4TWM2OD1yLkS0NVk3KM7:TR?= MXfTRW5ITVJ?
K-562 MkTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVTUNWxqUUN3ME2wMlQ1QTZ5IN88US=> NUnkNFU3W0GQR1XS
D-336MG MoTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L5bGlEPTB;MD61NFMxPCEQvF2= NXPkbpZqW0GQR1XS
NOS-1 MlXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fZc2lEPTB;MD62NFUzQSEQvF2= NVPx[IltW0GQR1XS
EW-24 NWHlTI91T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTBwNkK2PVMh|ryP MlOxV2FPT0WU
BV-173 MonhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHZO21KSzVyPUCuOlUzPDlizszN Ml;wV2FPT0WU
NCCIT M3rHe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4r3b2lEPTB;MD63N|IyQCEQvF2= MWHTRW5ITVJ?
NCI-H1436 MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUWzNlg6UUN3ME2wMlc6ODR7IN88US=> M2DCVnNCVkeHUh?=
BB30-HNC NFXDN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojWTWM2OD1yLki2NlA{KM7:TR?= NGLGWmhUSU6JRWK=
TE-8 M1\PRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwOEeyO|Uh|ryP Mn3CV2FPT0WU
A704 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTOfFI3UUN3ME2wMlg6OjFizszN M3vv[XNCVkeHUh?=
TK10 M4C2ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTBwOUC2Olkh|ryP Mn;PV2FPT0WU
KS-1 NULBW4FST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwMUm3O|kh|ryP Ml3oV2FPT0WU
C2BBe1 NXrENXNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyd3NjUUN3ME2xMlIxPTB5IN88US=> NEPIXJpUSU6JRWK=
RXF393 M2rRSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPNRolkUUN3ME2xMlI1OzZizszN NF\QRoNUSU6JRWK=
KGN M3X1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwMke2PFch|ryP M3XRT3NCVkeHUh?=
NB69 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XR[WlEPTB;MT6zO|Q6PyEQvF2= MmC0V2FPT0WU
TE-11 NYfsS3h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTFwNEO0NVgh|ryP NFHpN4JUSU6JRWK=
TE-1 MoK3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrOcVBKSzVyPUGuOFQyODVizszN MnzwV2FPT0WU
ST486 M1H5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTiUJBEUUN3ME2xMlQ2QDV{IN88US=> MUHTRW5ITVJ?
HOP-62 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrGfohJUUN3ME2xMlUxOjR4IN88US=> MkXmV2FPT0WU
EW-16 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwNUWwPFMh|ryP M{fnSHNCVkeHUh?=
LB1047-RCC MkezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrnTWM2OD1zLkW1OFU{KM7:TR?= NH32dYpUSU6JRWK=
TE-10 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDiTWM2OD1zLk[2NlUzKM7:TR?= MWTTRW5ITVJ?
RL95-2 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrYTWM2OD1zLk[2PVAzKM7:TR?= NVXSfoM6W0GQR1XS
DOHH-2 M4\x[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTFwN{G3PFIh|ryP M1KwfHNCVkeHUh?=
MFH-ino MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NULNXHNSUUN3ME2xMlc4QDdizszN NVexU4dYW0GQR1XS
GB-1 M{XCNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwN{m4N|Mh|ryP MoHzV2FPT0WU
SK-N-DZ MkjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXkTWM2OD1zLki0Olg5KM7:TR?= Ml;uV2FPT0WU
OS-RC-2 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfURlc{UUN3ME2xMlg5PTd2IN88US=> NULRUpo1W0GQR1XS
SW982 M1\4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFWxXYJKSzVyPUGuPVIxQTNizszN M3[zbXNCVkeHUh?=
KALS-1 M1;ENWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrQ[YFbUUN3ME2xMlk5PzJ{IN88US=> NXf3d|Z3W0GQR1XS
TGBC24TKB NF31[GtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPZTWM2OD1{LkC1PVU5KM7:TR?= NWnIcJV4W0GQR1XS
GI-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3MTWM2OD1{LkG2NFg1KM7:TR?= NET5fFNUSU6JRWK=
SW962 MknmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWW2[FB1UUN3ME2yMlE4OTd6IN88US=> NF\FRXhUSU6JRWK=
SW872 M{L3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvGfpVOUUN3ME2yMlE5PTB5IN88US=> MmDsV2FPT0WU
NCI-H747 NV7LfWhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTq[ItKSzVyPUKuNlU4OTRizszN MW\TRW5ITVJ?
MZ1-PC NWTOS49tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3KTnI{UUN3ME2yMlI6OzV4IN88US=> NX3WeZA{W0GQR1XS
MSTO-211H Mni0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzTTWM2OD1{LkO1O|I{KM7:TR?= MorHV2FPT0WU
BL-70 NXHQb4xKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXe2UIR3UUN3ME2yMlQ4PDJ{IN88US=> NGnmPW1USU6JRWK=
SW954 MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrQTWM2OD1{LkW3OFA5KM7:TR?= MkXYV2FPT0WU
SNB75 M3nIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17vNmlEPTB;Mj62PFU6PCEQvF2= MlzyV2FPT0WU
IST-SL2 NU\G[otUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfld3dKSzVyPUKuO|I{PzlizszN NWrjeGdrW0GQR1XS
GCIY MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\Vc2lEPTB;Mj64O|AxPSEQvF2= NIrHOXhUSU6JRWK=
KU812 NFu1XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnVN2xKSzVyPUOuNFUzQTlizszN MlW4V2FPT0WU
LXF-289 NH3tPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHGTIRKSzVyPUOuNVIyODlizszN Mkm4V2FPT0WU
ETK-1 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLPR|JKSzVyPUOuNlA4PjdizszN MXHTRW5ITVJ?
SF126 M1PCeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;KbI5KSzVyPUOuN|EyPzRizszN NEn3OWJUSU6JRWK=
LC-2-ad NWPxZ|ltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLPbHJHUUN3ME2zMlU2PyEQvF2= NEnybZBUSU6JRWK=
KNS-42 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHyeIRKSzVyPUOuOlUh|ryP NIq3fXlUSU6JRWK=
OVCAR-4 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjtNXh5UUN3ME2zMlc{PDN|IN88US=> M3XLZ3NCVkeHUh?=
PF-382 MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HHdmlEPTB;Mz64N|Y6QCEQvF2= NYfOZWZRW0GQR1XS
SH-4 NYHyeGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPkOGdKSzVyPUSuNlUzPTlizszN NXq1TYxZW0GQR1XS
KM12 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1frRmlEPTB;ND6zNlQyPiEQvF2= MYrTRW5ITVJ?
NB5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7KdGRKSzVyPUSuOFE5PjRizszN NUnwW5ZQW0GQR1XS
KURAMOCHI MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\lbGFKSzVyPUSuOlUzPTZizszN M3TYV3NCVkeHUh?=
Becker MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PFfWlEPTB;ND62OlQyPiEQvF2= NInE[3VUSU6JRWK=
MV-4-11 M3X6b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnyfZczUUN3ME20MlgyOzR2IN88US=> MXrTRW5ITVJ?
KINGS-1 NH\melBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLhTWM2OD12LkiyN|c{KM7:TR?= NEn3XnhUSU6JRWK=
LS-123 NVy0VmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\3TWM2OD13LkS5Olg1KM7:TR?= MVfTRW5ITVJ?
SF268 NFvHfoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\ybG1lUUN3ME21MlYyOjZ{IN88US=> MV3TRW5ITVJ?
A388 Ml3uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi3TWM2OD13Lk[zOlY4KM7:TR?= M2\OVnNCVkeHUh?=
NMC-G1 NFzaWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFewRWxKSzVyPU[uNFE5OTFizszN NH7mdnBUSU6JRWK=
CGTH-W-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjSPFdKSzVyPU[uNFIxPzVizszN M4PUXXNCVkeHUh?=
ES4 M3LvT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXqTWM2OD14LkWzNFc1KM7:TR?= MnHXV2FPT0WU
SR NEfsR2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTmcYpPUUN3ME22MlU5QDB5IN88US=> NX7CTIZYW0GQR1XS
BB49-HNC MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTBWHp7UUN3ME22Mlc{OjB4IN88US=> NEfQTI5USU6JRWK=
KLE NXHjU4prT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVZWlEPTB;Nj63PFM4PyEQvF2= NEXWdINUSU6JRWK=
HUTU-80 NEPBWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTWXow1UUN3ME22Mlk5PDZ4IN88US=> M3zpenNCVkeHUh?=
SNU-C2B MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\TW2hPUUN3ME23MlgzPzN5IN88US=> NEexcJdUSU6JRWK=
BB65-RCC NYLSXGo5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17Z[2lEPTB;Nz65OFkxPCEQvF2= MnXuV2FPT0WU
QIMR-WIL M3;PZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmn5TWM2OD16LkSyPFA5KM7:TR?= M3TjRnNCVkeHUh?=
GDM-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRThwOUeyPVIh|ryP MX;TRW5ITVJ?
LC4-1 MmHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPVTWM2OD17LkCwPVEyKM7:TR?= MkXDV2FPT0WU
MLMA Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu3TWM2OD17LkG1NFA3KM7:TR?= MlTHV2FPT0WU
EoL-1-cell NEDsVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTlwM{CxPVIh|ryP M4jQWXNCVkeHUh?=
BOKU MlvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlS3TWM2OD17Lkm2OFY3KM7:TR?= MlX1V2FPT0WU
EVSA-T M2TMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\OTWM2OD1zMD62OVY5KM7:TR?= M2jZR3NCVkeHUh?=
D-283MED Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnMTJJjUUN3ME2xNE46OTd4IN88US=> NV7Yc5VYW0GQR1XS
NB1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDydW9XUUN3ME2xNU4xOjR{IN88US=> M1rtbXNCVkeHUh?=
RPMI-8402 M1PiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2nUc2lEPTB;MUGuNVc5KM7:TR?= NF\xfIxUSU6JRWK=
NCI-H1355 M2rMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH\vNGdKSzVyPUGxMlE5ODZizszN MUHTRW5ITVJ?
NB7 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzWTWM2OD1zMT6zNlk4KM7:TR?= NUj0ZZZmW0GQR1XS
RPMI-6666 NGruUlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrIZXRXUUN3ME2xNk46PTZ5IN88US=> NFT5SVNUSU6JRWK=
697 NH35cnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXBTWM2OD1zMz6yO|AyKM7:TR?= NXXCV5luW0GQR1XS
CTB-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\WZ5pzUUN3ME2xN{42QTR6IN88US=> M2X3ZnNCVkeHUh?=
VA-ES-BJ M{SzSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoH5TWM2OD1zMz65NlM1KM7:TR?= NVvHWmlJW0GQR1XS
BE-13 M1;XUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnJS|NKSzVyPUG0MlM6OTVizszN MXvTRW5ITVJ?
SKM-1 M3rncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2O5WWlEPTB;MUSuOFQ6QSEQvF2= MVnTRW5ITVJ?
TE-6 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PseGlEPTB;MUSuO|U6OSEQvF2= MlT1V2FPT0WU
LB771-HNC NW